Corpus Intelligence IC Memo — HARLEM HOSPITAL CENTER 2026-04-26 03:43 UTC
IC Memo — HARLEM HOSPITAL CENTER
Investment Committee Memorandum | NY | 217 beds | Grade C | EBITDA uplift $38.2M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

HARLEM HOSPITAL CENTER

CCN 330240 | NEW YORK, NY | 217 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

HARLEM HOSPITAL CENTER is a 217-bed suburban community hospital in NEW YORK, NY with $519.6M in net patient revenue and a -22.9% operating margin. The hospital serves a payer mix of 12.0% Medicare, 17.6% Medicaid, and 70.5% commercial.

Thesis: Undervalued. Our ML models identify $38.2M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -22.9% to -15.6% (+736bps).

Net Revenue HCRIS$519.6M
Current EBITDA COMPUTED$-119.1M
Operating Margin COMPUTED-22.9%
Occupancy HCRIS73.4%
Revenue / Bed COMPUTED$2.4M
Net-to-Gross HCRIS50.0%
Distress Probability ML46.2%

2. Market Context & Competitive Position

196
NY Hospitals
-17.5%
State Median Margin
96
Comparable Hospitals

NY has 196 Medicare-certified hospitals with a median operating margin of -17.5%. The target's margin of -22.9% places it below the state median. Among 96 size-comparable peers (108-434 beds), the median margin is -17.8%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (108-434), prioritizing same-state peers. 96 hospitals in the comp set.

HospitalStateBedsRevenueMargin
HARLEM HOSPITAL CENTER (Target)NY217$519.6M-22.9%
LENOX HILL HOSPITALNY415$1.32B-35.1%
HOSPITAL FOR SPECIAL SURGERYNY200$1.12B-29.3%
NYC HEALTH+HOSPITAL/KINGS COUNNY381$1.03B-15.0%
ST. FRANCIS HOSPITALNY364$889.3M2.0%
WHITE PLAINS HOSPITALNY292$884.7M8.7%
ELMHURST HOSPITAL CENTERNY358$862.7M-9.5%
ROSWELL PARK CANCER INSTITUTENY142$772.3M-40.1%
VASSAR BROTHERS MEDICAL CENTERNY340$735.1M-2.6%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $38.2M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$10.9M+210bp18mo
Cost to Collect4.5%2.5%$10.4M+200bp12mo
Denial Rate Reduction12.0%6.5%$10.3M+198bp12mo
A/R Days Reduction5200.0%3800.0%$6.3M+122bp9mo
Clean Claim Rate88.0%96.0%$333K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$10.9M
Cost to Collect
$10.4M
Denial Rate Reduction
$10.3M
A/R Days Reduction
$6.3M
Clean Claim Rate
$333K
Total EBITDA Uplift$38.2M
Current EBITDA$-119.1M
+ RCM Uplift+$38.2M
Pro Forma EBITDA$-80.9M
Current Margin-22.9%
Pro Forma Margin-15.6%
WC Released (1x)$19.9M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-183.3M$-403.3M0.00x-100.0%
Base (11x exit)10.0x11.0x$-183.3M$-503.2M0.00x-100.0%
Bull Case9.0x11.0x$-165.0M$-436.5M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-165.0M$-524.9M0.00x-100.0%
Bear Case11.0x10.0x$-201.6M$-535.1M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-201.6M$-654.1M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 96 hospitals with 108-434 beds
  • Same-state prioritization (n=97)
  • Comp margins: P25=-28.5% / P50=-17.8% / P75=-9.3%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.